Sentinel node biopsy in breast cancer patients undergoing induction chemotherapy should be performed prior to chemotherapy by Piekarski, Janusz
267
Short review
NOWOTWORY Journal of Oncology 
2017, volume 67, number 4, 267–269
DOI: 10.5603/NJO.2017.0043
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Clinical Department of Surgical Oncology, Medical University of Łódź, Poland
Sentinel node biopsy in breast cancer patients undergoing induction 
chemotherapy should be performed prior to chemotherapy
Janusz Piekarski
Presently, preoperative chemotherapy is administered ever more frequently in breast cancer patients. It is administered 
in both non-resectable and resectable patients, i.e. those in whose case it is possible to undertake surgical treatment 
without the use of chemotherapy. Sentinel node biopsy may only be performed in patients classified as cN0. Hence, 
the dilemma of whether sentinel node biopsy should be performed before or after preoperative chemotherapy 
applies only to those patients in whom there are no axillary lymph node metastases before the chemotherapy in 
question (cN0). Even though the question of whether to perform sentinel node biopsy before or after preoperative 
chemotherapy in cN0 patients still remains open, a number of indicators testifying to the quality of the results obta-
ined, tend to point in favour of sentinel node biopsy performed prior to chemotherapy. When sentinel node biopsy 
is performed before induction chemotherapy, the node identification rate is higher (100% vs 95%), and the rate of 
false negative results is lower (7.4% vs 11.4%) than in the case of a post-chemotherapy biopsy. 
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Presently, preoperative chemotherapy is administered 
ever more frequently in breast cancer patients. It is admi-
nistered in both non-resectable and resectable patients, i.e. 
those in whose case it is possible to undertake surgical tre-
atment without the use of chemotherapy, but at the same 
time we know that neoadjuvant chemotherapy may further 
improve our treatment results. Preoperative chemotherapy 
is administered both in patients with baseline axillary lymph 
node involvement as well as in those without. Patients with 
lymph node involvement, reported prior to chemotherapy, 
may undergo complete remission, while in patients without 
baseline axillary lymph node involvement, metastases may 
sadly develop at a later stage. Hence, it is of key significance 
to be able to assess the condition of axillary lymph nodes 
accurately. When the metastases are overt, there are usually 
no diagnostic controversies. The doubts are there, however, 
when the physical examination and imaging tests indicate 
no lymph node metastases. We know that the sensitivity 
of those tests is far from ideal, and that only the sentinel 
node biopsy is the source of a definite confirmation of the 
presence of lymph node involvement or lack thereof.
A sentinel node biopsy may only be performed in pa-
tients classified as cN0. Hence, the dilemma of whether 
a sentinel node biopsy should be performed before or after 
preoperative chemotherapy applies only to those patients in 
whom there are no axillary lymph node metastases before 
the chemotherapy in question (cN0). There is no dilemma, 
on the other hand, when lymph node involvement is re-
ported prior to chemotherapy. In the latter case, there are 
no indications for a sentinel node biopsy. It may only be 
performed after chemotherapy, when complete clinical 
remission of lymph node metastases has been observed. 
Therefore, cN+ patients, prior to chemotherapy, should be 
excluded from the discussion that follows. Similarly, there 
are no indications for sentinel node biopsy following pre-
operative chemotherapy, when axillary lymph node invo-
lvement is clinically confirmed. That clinical situation will 
not be discussed here either. 
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The question of whether to perform sentinel node 
biopsy before or after neoadjuvant chemotherapy in cN0 
patients has remained open [1]. Contemporary guidelines 
are not helpful in resolving the dilemma either. The NCCN 
recommendations indicate that biopsy may be performed 
before or after chemotherapy [2], which goes to say that 
the decision is to be taken on a case-by-case basis by the 
treatment team.
What speaks in favour of a sentinel node biopsy perfor-
med prior to neoadjuvant chemotherapy? First and fore-
most, a pre-chemotherapy biopsy makes it possible to as-
sess the degree of disease advancement accurately enough, 
prior to the initiation of treatment. When there is no sentinel 
lymph node involvement, we may safely withdraw from 
post-chemotherapy axillary lymph node dissection. That 
approach is also reflected in the NCCN guidelines [2]. If, on 
the other hand, there is sentinel lymph node involvement, 
we may correctly qualify the patient for axillary lymph node 
dissection, and plan adjuvant radiotherapy appropriately. 
In that respect, pre-chemotherapy sentinel node biopsy is 
revealed as advantageous. We know that chemotherapy will 
result in the complete remission of axillary lymph node me-
tastases in 20–40% of patients diagnosed with lymph node 
involvement prior to treatment [3]. Radiotherapy should 
later be offered to those patients, even if there has been 
complete remission of the axillary lymph node lesions. Thus, 
if we fail to perform sentinel node biopsy before preoperati-
ve chemotherapy, we will have no knowledge of the baseline 
axillary lymph node metastases, and we will be oblivious 
of the fact that there are indications for adjuvant axillary 
radiotherapy. Performing a sentinel lymph node biopsy only 
after neoadjuvant chemotherapy may thus result in a failure 
to offer a significant part of treatment to some patients.
An obvious question that arises is why not perform 
sentinel lymph node biopsy twice, i.e. before and after neo-
adjuvant chemotherapy? It could be the optimum solution. 
It is not, though, and study results remain incontrovertible 
in that respect. 
The first study worth mentioning here is the SENTINA 
trial, a multi-centre study carried out in 103 therapeutic 
centres across Germany and Austria [1]. The study involved 
over 2200 patients. One study arm included patients with 
sentinel lymph node involvement, reported prior to neo-
adjuvant chemotherapy, who underwent chemotherapy, 
followed by a second sentinel node biopsy with axillary 
lymph node dissection. Thanks to that approach, it was 
possible to assess the percentage of correctly identified 
sentinel lymph nodes, and to determine the percentage of 
false negative results of the second sentinel node biopsy. 
As a result of the second biopsy, sentinel lymph nodes were 
identified in 61% of the cases only, which is an extremely 
low detection rate. In 52% of the cases, the results obtained 
were false negatives, which means that no metastases were 
found in the sentinel lymph node, but they were detected 
in other axillary lymph nodes, removed during the lymph 
node dissection procedure. That seems, on the other hand, 
an extremely high false-negative rate. 
The second, more recent study was carried out by Swe-
dish researchers [4]. Quality indicators of the second sentinel 
lymph node biopsy were revealed as slightly better than 
the ones generated in the SENTINA trial, but they are still 
largely unacceptable. The study, which involved 224 female 
patients, resulted in a 70% sentinel node detection rate, and 
a 25% false-negative rate.
Both of the above mentioned studies demonstrate that 
a repeated sentinel lymph node biopsy in patients subjected 
to preoperative chemotherapy is completely unreliable. 
Thus, a sentinel node biopsy should only be perfor-
med once. The decision remains to be taken as to when to 
perform it.
As discussed above, what speaks in favour of the sen-
tinel lymph node biopsy performed before neoadjuvant 
chemotherapy in cN0 patients is the fact that one can assess 
the degree of disease advancement prior to the initiation of 
treatment. Another reason for performing the biopsy before 
rather than after preoperative chemotherapy in cN0 patients 
involves the biopsy reliability indicators, i.e. the sentinel 
node detection rate and the false-negative rate. 
As regards the detection rate, a sentinel node biopsy 
performed before preoperative chemotherapy is absolutely 
unrivalled, with the rate reaching 99–100%. The result is 
based on the SENTINA study [1], involving 1022 pre-che-
motherapy biopsies, and on the Swedish study [4], which 
involved 224 biopsies.
When sentinel node biopsy is performed after preope-
rative chemotherapy, its results are much less reliable. For 
comparison, I reviewed the results of a meta-analysis inc-
luding 17 studies, which involved over 1700 breast cancer 
patients [5]. Detection rates ranged from 83% to 100%. 
The authors of the meta-analysis calculated the average 
detection rate as 95%. However, a further analysis of the 
individual studies included in the meta-analysis indicated 
that the studies that reported detection rates of 100% were 
very “small”. In all those studies, a post-chemotherapy biopsy 
was only performed in 17 patients, which suggests that the 
reliability of those results is rather poor [6, 7]. 
The other indicator which should be examined is the 
false-negative rate. In the early studies on the use of sentinel 
node biopsy before neoadjuvant chemotherapy, false-nega-
tive rates were very low, amounting to 0% in selected trials. 
Such a result would be considered ideal, but is highly unli-
kely, and thus unreliable. The studies which generated such 
results involved as few as 11 or 15 biopsies, which is why 
no reliable conclusions could be drawn on their basis [8, 9]. 
On the other hand, the previously mentioned Swedish 
study did lead to reliable results, as it involved a group of 224 
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subjects [4]. In that study, the false-negative rate was 7.4%, 
which is not that small a number. It should be emphasised 
here that the false negative results reported also included 
cases of micrometastases only. Their clinical significance 
after chemotherapy is not yet known, which is why they 
were treated as significant to ensure patients’ safety. What 
was the reason for the high rate of false negative results? 
Disease progression may not be excluded, which is why the 
authors came to the conclusion that axillary lymph node 
dissection may be aborted, provided there is no sentinel 
lymph node involvement prior to chemotherapy, and there 
is a good response to chemotherapy. 
The false-negative rate is much higher, when the biop-
sy is performed after neoadjuvant chemotherapy. In the 
above quoted meta-analysis, whose results were published 
in 2013, it was calculated that the average false-negative 
rate for post-chemotherapy sentinel node biopsy totalled 
11.4% [5]. However, in some of the studies included in the 
meta-analysis, the rates were as high as 14%, 16%, 17% or 
even 28% [5]. 
In summary, both indicators favour the sentinel lymph 
node biopsy performed before neoadjuvant chemotherapy. 
When sentinel node biopsy is performed prior to chemothe-
rapy, detection rates are higher (100% vs 95%), and false-
-negative rates are lower (7.4% vs 11.4%) than in the case 
of a post-chemotherapy biopsy.
As mentioned before, one argument against the sentinel 
node biopsy performed before neoadjuvant chemotherapy is 
the possibility of obtaining complete clinical remission in the 
lymph nodes of 20–40% of the chemotherapy patients. It goes 
to say that if the sentinel node biopsy is performed before 
neoadjuvant chemotherapy, and lymph node involvement is 
confirmed, standard procedure involves post-chemotherapy 
lymph node dissection, even though there may be comple-
te remission of the lymph node metastases in 20–40% of 
the patients as a result of the chemotherapy administered. 
Thus, some of the patients may be overtreated. How big of a 
problem is it, though? Amongst the cN0 patients enrolled in 
the SENTINA study, sentinel node biopsy performed prior to 
chemotherapy confirmed lymph node involvement in 40% 
of them. If remission occurred in 20–40% of the cases, the risk 
of surgical overtreatment concerned 8–16% of the patients 
involved. In order to establish whether that number is high or 
low, we have to decide what we fear more: the idea of treating 
people who may not need the treatment offered or failure to 
undertake treatment in those who may need it. 
And what other arguments are there against sentinel 
node biopsy performed after neoadjuvant chemotherapy? 
Human biology. Studies have demonstrated that following 
chemotherapy, lymphatic vessels undergo remodelling, 
with fibrotic lesions that may compromise lymphatic dra-
inage. Advocates of post-chemotherapy biopsy indicate 
that lymphatic drainage is altered only in 5% of the cases 
[5]. But it is this 5% that matters, as this is exactly the diffe-
rence between the sentinel node detection rates and the 
false-negative rates obtained in pre-chemotherapy and 
post-chemotherapy biopsies. And the difference points 
in favour of the biopsy performed prior to preoperative 
chemotherapy.
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